We would like to highlight ThermoGenesis Corp. (NASDAQ: KOOL). The company is a supplier of products that process, store and administer therapeutic doses of stem cells for treatment of disease and injury. Its products harvest stem cells, wound healing proteins or growth factors from the blood, or tissue, of a single donor and are administered to that donor or a matched patient. The Company’s devices and disposables are used by physicians, researchers, hospitals and blood banks in four distinct markets: private cord blood banking, public cord blood banking, wound care and the emerging stem cell therapy market that use adult cells.
In the company’s news yesterday,
ThermoGenesis Corp. announced the addition of 10 new distributors for its BioArchive System, a technology used to cryopreserve and archive stem cells and tissue. Three of the 10 distributors also hold the right to distribute ThermoGenesis’ AutoXpress AXP Platform, which is used to harvest stem cells in a closed system from umbilical cord blood.
The distributors will target key geographies outside the United States for the sale of BioArchive, including the UK, Russia, the Baltic region, China, Hong Kong, South Korea, a number of Middle Eastern and African countries, and Central and South America. While ThermoGenesis focuses on marketing the BioArchive directly in North America, the agreement calls for the distributors to target Russia, China, and Central and South America as well.
“Our ability to achieve these agreements in a short period of time speaks not only to the effectiveness of our sales organization, but also to the potential market opportunity for our offerings,” Dr. William Osgood, CEO of ThermoGenesis stated in the press release.
“We are particularly encouraged by the fact that many of these distributors previously sold one or more of our offerings — including a number that were previously successful selling the BioArchive — and have developed solid relationships with the market in their respective geographies. As a result, we expect minimal disruption to our selling efforts during this transition,” Dr. Osgood stated.
ThermoGenesis also recently announced the renovation of its international distribution agreement with GE Healthcare (GEHC) effective July 1, 2008, in which GEHC returned worldwide rights to distribute the BioArchive System to ThermoGenesis, while continuing as exclusive international distributor of AXP Platform products for cord blood applications.
“We will continue to fill out distributor relationships in additional geographies — including the Scandinavian countries — over the coming months, and are initiating discussions with potential distribution organizations regarding our recently-authorized MarrowXpress (MXP) device, which is for use in a clinical laboratory setting or intraoperatively for preparation of a cell concentrate from bone marrow,” Dr. Osgood stated. “We are having ongoing discussions with GEHC about other potential areas of regenerative medicine that we can develop jointly.”
About QualityStocks
QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.
To sign up for “The QualityStocks Daily Newsletter” please visit http://www.qualitystocks.net/
Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
